Discovery of spirocyclic sulfonamides as potent Akt inhibitors with exquisite selectivity against PKA

Bioorganic and Medicinal Chemistry Letters

Volumn 21, Issue 8, 2011, Pages 2335-2340

  Xu, Rui ^a   Banka, Anna ^a   Blake, James F ^a   Mitchell, Ian S ^a   Wallace, Eli M ^a   Bencsik, Josef R ^a   Kallan, Nicholas C ^a   Spencer, Keith L ^a   Gloor, Susan L ^a   Martinson, Matthew ^a   Risom, Tyler ^a   Gross, Stefan D ^a   Morales, Tony H ^a   Wu, Wen I ^a   Vigers, Guy P A ^a   Brandhuber, Barbara J ^a   Skelton, Nicholas J ^b  

^a ARRAY BIOPHARMA INC   (United States)

^b GENENTECH INC   (United States)

Author keywords

Akt; Kinase; PKA; Selectivity; Spiro

Indexed keywords

CYCLIC AMP DEPENDENT PROTEIN KINASE; PROTEIN KINASE B INHIBITOR; SPIRO COMPOUND; SULFONAMIDE;

ARTICLE; DRUG DESIGN; DRUG POTENCY; DRUG SCREENING; DRUG SELECTIVITY; DRUG STRUCTURE;

BINDING SITES; COMPUTER SIMULATION; CRYSTALLOGRAPHY, X-RAY; CYCLIC AMP-DEPENDENT PROTEIN KINASES; DRUG EVALUATION, PRECLINICAL; PROTEIN KINASE INHIBITORS; PROTO-ONCOGENE PROTEINS C-AKT; SPIRO COMPOUNDS; STRUCTURE-ACTIVITY RELATIONSHIP; SULFONAMIDES;

EID: 79953269490     PISSN: 0960894X     EISSN: None     Source Type: Journal    
DOI: 10.1016/j.bmcl.2011.02.098     Document Type: Article

References (26)

1. S. Hanks, and T. Hunter FASEB 9 1995 576
2. M.J. Zinda, M.A. Johnson, J.D. Paul, C. Horn, B.W. Konicek, Z.H. Lu, G. Sandusky, J.E. Thomas, B.L. Neubauer, M.T. Lai, and J.R. Graff Clin. Cancer Res. 7 2001 2475
3. S. Masure, B. Haefner, J.J. Wesselink, E. Hoefnagel, E. Mortier, P. Verhasselt, A. Tuytelaars, R. Gordon, and A. Richardson Eur. J. Biochem. 265 1999 353
4. J. Li, C. Yen, D. Liaw, K. Podsypanina, S. Bose, S.I. Wang, J. Puc, C. Miliaresis, L. Rodgers, R. McCombie, S.H. Bigner, B.C. Giovanella, M. Ittmann, B. Tycko, H. Hibshoosh, M.H. Wigler, and R. Parsons Science 275 1997 1943
5. T. Maehama, and J.E. Dixon J. Biol. Chem. 273 1998 13375
6. P.A. Steck, M.A. Pershouse, S.A. Jasser, W.K.A. Yung, H. Lin, A.H. Ligon, L.A. Langford, M.L. Baumgard, T. Hattier, T. Davis, C. Frye, R. Hu, B. Swedlund, D.H.R. Teng, and S.V. Tavtigian Nat. Genet. 15 1997 356
7. P. Liu, H. Cheng, T.M. Roberts, and J.J. Zhao Nature Rev. Drug Discov. 8 2009 627
8. For recent reviews on Akt see: Q. Li Expert Opin. Ther. Pat. 17 2007 1077
9. L.S. Steelman, K.M. Stadelman, W.H. Chappell, S. Horn, J. Bäsecke, M. Cervello, F. Nicoletti, M. Libra, F. Stivala, A.M. Martelli, and J.A. McCubrey Expert Opin. Ther. Targets 12 2008 1139
10. C.W. Lindsley, S.F. Barnett, M.E. Layton, and M.T. Bilodeau Curr. Cancer Drug Targets 8 2008 7
11. C.W. Lindsley, S.F. Barnett, M. Yaroschak, M.T. Bilodeau, and M.E. Layton Curr. Top. Med. Chem. 7 2007 1349
12. C.W. Lindsley Curr. Top. Med. Chem. 10 2010 458
13. J.Q. Cheng, C.W. Lindsley, G.Z. Cheng, H. Yang, and S.V. Nicosia Oncogene 24 2005 7482
14. E. Fayard, L. Tintignac, A. Baudry, and B. Hemmings J. Cell Sci. 118 2005 5675
15. K.M. Nicholson, and N.G. Anderson Cell. Signalling 14 2002 381
16. N.C. Kallan, K.L. Spencer, R. Xu, J.F. Blake, J. Heizer, J.R. Bencsik, I.S. Mitchell, S.L. Gloor, M. Martinson, T. Risom, S. Gross, T.H. Morales, W. Wu, G.P.A. Vigers, B.J. Brandhuber, and N.J. Skelton Bioorg. Medi. Chem. Lett. 21 2011 2410
17. 3, THF, HOAc, rt, 16 h, 91% yield for two steps; (5) amide hydrolysis with 9N HCl, dioxane, reflux, 36 h, 73%.
18. J. Kitchin, R.C. Bethell, N. Cammack, S. Dolan, D.N. Evans, S. Holman, D.S. Holmes, P. McMeekin, C.L. Mo, N. Nieland, D.C. Orr, J. Saunders, B.E.V. Shenoy, I.D. Starkey, and R. Storert J. Med. Chem. 37 1994 3707
19. J.F. Blake, N.C. Kallan, D. Xiao, R. Xu, J.R. Bencsik, N.J. Skelton, K.L. Spencer, I.S. Mitchell, R. Woessner, S.L. Gloor, T. Risom, S.D. Gross, M. Martinson, T. Morales, G.P.A. Vigers, and B.J. Brandhuber Bioorg. Med. Chem. Lett. 20 2010 5607
20. J.R. Bencsik, D. Xiao, J.F. Blake, N.C. Kallan, I.S. Mitchell, K.L. Spencer, R. Xu, S.L. Gloor, M. Martinson, T. Risom, R. Woessner, F. Dizon, W. Wu, G.P.A. Vigers, B.J. Brandhuber, N.J. Skelton, W.W. Prior, and L.J. Murray Bioorg. Med. Chem. Lett. 20 2010 7037
21. For pyrrolo[2,3-d]pyrimidine Akt inhibitors with various PKA selectivity profiles see: J.J. Caldwell, T.G. Davies, A. Donald, T. McHardy, M.G. Rowlands, G.W. Aherne, L.K. Hunter, K. Taylor, R. Ruddle, F.I. Raynaud, M. Verdonk, P. Workman, M.D. Garrett, and I. Collins J. Med. Chem. 51 2008 2147
22. B. Lippa, G. Pan, M. Corbett, C. Li, G.S. Kauffman, J. Pandit, S. Robinson, L. Wei, E. Kozina, E.S. Marr, G. Borzillo, E. Knauth, E.G. Barbacci-Tobin, P. Vincent, M. Troutman, D. Baker, F. Rajamohan, S. Kakar, T. Clark, and J. Morris Bioorg. Med. Chem. Lett. 18 2008 3359
23. T. McHardy, J.J. Caldwell, K. Cheung, L.J. Hunter, K. Taylor, M. Rowlands, R. Ruddle, A. Henley, A. Brandon, H. De, M. Valenti, T.G. Davies, L. Fazal, L. Seavers, F.I. Raynaud, S.A. Eccles, G.W. Aherne, M.D. Garrett, and I. Collins J. Med. Chem. 53 2010 2239
24. K.D. Freeman-Cook, C. Autry, G. Borzillo, D. Gordon, E. Barbacci-Tobin, V. Bernardo, D. Briere, T. Clark, M. Corbett, J. Jakubczak, S. Kakar, E. Knauth, B. Lippa, M.J. Luzzio, M. Mansour, G. Martinelli, M. Marx, K. Nelson, J. Pandit, F. Rajamohan, S. Robinson, C. Subramanyam, L. Wei, M. Wythes, and J. Morris J. Med. Chem. 53 2010 4615
25. Atomic co-ordinates of the structure 5 bound to Akt1 were deposited with the RCSB Protein Data Bank (PDB) under the accession code 3QKM.
26. Such a linkage was compatible with the conformation of compound 5 observed in the co-crystal structure with Akt1 (Fig. 3).